Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

NCT02343835
completednot_applicable

Percutaneous Irreversible Electroportion for Unresectable Breast Cancer

NCT02340858
completednot_applicable

Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

NCT02352935

Clinical Trials (3)

Showing 3 of 3 trials
NCT02343835Not Applicable

Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

Completed
NCT02340858Not Applicable

Percutaneous Irreversible Electroportion for Unresectable Breast Cancer

Completed
NCT02352935Not Applicable

Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3